Published March 14, 2025
This research evaluates the cost-effectiveness of four different antiobesity medications compared to lifestyle modification alone for US adults. Using a microsimulation model, the study projected the lifetime health benefits and costs of these treatments for a large, representative sample of the US population. While medications like tirzepatide and semaglutide demonstrated significant improvements in health outcomes by preventing conditions such as obesity, diabetes, and cardiovascular disease, the analysis concludes they are not cost-effective at their current prices. The findings indicate that substantial price reductions are necessary for these newer medications to meet standard cost-effectiveness benchmarks and improve equitable access. The study also highlights how other, less expensive medications like naltrexone-bupropion can be cost-saving alternatives.
Audio Overview
(from Google NotebookLM) (14 minutes and 41 seconds)
